UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PALB2, gène majeur de susceptibilité au cancer du sein

Gynécologie Obstétrique Fertilité & Sénologie, 2018-11, Vol.46 (10-11), p.701-705

2018

Volltextzugriff (PDF)

ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer

Annals of oncology, 2005-01, Vol.16 (suppl-1), p.i7-i9

2005

Volltextzugriff (PDF)

70 Gy versus (vs) 80 Gy Dose Escalation Getug 06 French Trial for Localized Prostate Cancer: Mature Results

International journal of radiation oncology, biology, physics, 2008, Vol.72 (1), p.S96-S97

2008

Volltextzugriff (PDF)

uPA/PAI-1, Oncotype DX™, MammaPrint® Valeurs pronostique et prédictive pour une utilité clinique dans la prise en charge du cancer du sein

Oncologie (Paris, France), 2014, Vol.16 (4), p.196-206

2014

Volltextzugriff (PDF)

Epirubicin-Based Chemotherapy in Metastatic Breast Cancer Patients: Role of Dose-Intensity and Duration of Treatment

Journal of clinical oncology, 2000-09, Vol.18 (17), p.3115-3124

the French Epirubicin Study Group

2000

Volltextzugriff (PDF)

Oncogénétique: estimation des besoins de la population en France pour les dix ans à venir

Bulletin du cancer, 2009-09, Vol.96 (9), p.875-900

2009

Volltextzugriff (PDF)

Cancer genetics: estimation of the needs of the population in France for the next ten years

Bulletin du cancer, 2009-09, Vol.96 (9), p.875

2009

Volltextzugriff (PDF)

335PBreast cancer (BC) treatment (tx) with everolimus (EVE) and exemestane (EXE) in hormone receptor positive (HR+)/ HER2-negative (HER2−) postmenopausal women: Final analysis of the French observational TANGO study

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1 2 mutations

European journal of human genetics : EJHG, 2011-05, Vol.19 (5), p.500-506

2011

Volltextzugriff (PDF)

Prise en charge des cancers du sein : le changement, c’est maintenant

Gynécologie Obstétrique Fertilité & Sénologie, 2017-01, Vol.45 (1), p.3-4

2017

Volltextzugriff (PDF)

Role of interstitial brachytherapy in oral and oropharyngeal carcinoma: Reflection of a series of 1344 patients treated at the time of initial presentation

Otolaryngology-head and neck surgery, 1996-12, Vol.115 (6), p.519-526

1996

Volltextzugriff (PDF)

Abstract P2-01-02: Heterogeneity and variability of human epidermal growth factor receptor 2 (HER2) expression on circulating tumor cells (CTC) in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab in a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG): COMET study

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P2-P2-01-02

2018

Volltextzugriff (PDF)

Abstract PD2-03: Circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) predictive value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: Results of a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG): COMET study

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD2-03-PD2-03

2019

Volltextzugriff (PDF)

1568P - The Use of Biosimilar Epoetins in the Management of Chemotherapy-Induced Anaemia (CIA) in Patients with Breast Cancer: A Subanalysis of the Orheo Study

Annals of oncology, 2012-09, Vol.23, p.ix506-ix506

2012

Volltextzugriff (PDF)

The Use of Biosimilar Epoetins in the Management of Chemotherapy-Induced Anaemia (CIA) in Patients with Breast Cancer: A Subanalysis of the Orheo Study

Annals of oncology, 2012-09, Vol.23, p.ix506

2012

Volltextzugriff (PDF)

The Use of Biosimilars in the Management of Chemotherapy-Induced Anaemia (CIA) in Solid Tumours, Lymphoma and Myeloma: the Orheo Study

Annals of oncology, 2012-09, Vol.23, p.ix504-ix505

2012

Volltextzugriff (PDF)

The Use of Biosimilar Epoetins in the Management of Chemotherapy-Induced Anaemia (CIA) in Patients with Lung Cancer: A Subanalysis of the Orheo Study

Annals of oncology, 2012-09, Vol.23, p.ix506

2012

Volltextzugriff (PDF)

1563P - The Use of Biosimilars in the Management of Chemotherapy-Induced Anaemia (CIA) in Solid Tumours, Lymphoma and Myeloma: the Orheo Study

Annals of oncology, 2012-09, Vol.23, p.ix504-ix505

2012

Volltextzugriff (PDF)

1569P - The Use of Biosimilar Epoetins in the Management of Chemotherapy-Induced Anaemia (CIA) in Patients with Lung Cancer: A Subanalysis of the Orheo Study

Annals of oncology, 2012-09, Vol.23, p.ix506-ix506

2012

Volltextzugriff (PDF)

Breast cancer clinical practice recommendations from Saint-Paul-de-Vence: excerpts concerning targeted therapies: Cours supérieur francophone de cancérologie, Saint-Paul-de-Vence

Targeted oncology, 2006-10, Vol.1 (4), p.228-238

2006

Volltextzugriff (PDF)

Abstract P2-12-02: Characteristics of the BRCA mutation profile of a population of patients with triple negative breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P2-P2-12-02

2013

Volltextzugriff (PDF)

Abstract P1-01-02: Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG): COMET study

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P1-P1-01-02

2017

Volltextzugriff (PDF)

Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas

Cancer, 2005-12, Vol.104 (12), p.2792-2797

2005

Volltextzugriff (PDF)

Summary version of the standards, options and recommendations for nonmetastatic breast cancer (updated January 2001)

British journal of cancer, 2003-08, Vol.89 (S1), p.S17-S31

2003

Volltextzugriff (PDF)

Place des biosimilaires de l’époétine dans le traitement des anémies secondaires à une chimiothérapie pour cancer des poumons : sous-analyse de l’étude ORHEO

Revue des maladies respiratoires, 2014-01, Vol.31, p.A28-A28

2014

Volltextzugriff (PDF)

26 – 50 von 202

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(184)
Mit Volltextzugriff
(176)

Publikationsform

Artikel
(200)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(89)
Female
(77)
Life Sciences & Biomedicine
(69)
Science & Technology
(69)
Middle Aged
(61)
Oncology
(56)
Aged
(54)
Adult
(50)
Male
(37)
Biological And Medical Sciences
(35)
Medical Sciences
(35)
Aged, 80 And Over
(30)
Breast Cancer
(28)
Retrospective Studies
(24)
Prognosis
(23)
Radiology, Nuclear Medicine & Medical Imaging
(21)
Tumors
(20)
Radiotherapy Dosage
(19)
Sciences Biologiques Et Medicales
(19)
Sciences Medicales
(19)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PALB2, gène majeur de susceptibilité au cancer du sein

ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer

70 Gy versus (vs) 80 Gy Dose Escalation Getug 06 French Trial for Localized Prostate Cancer: Mature Results

uPA/PAI-1, Oncotype DX™, MammaPrint® Valeurs pronostique et prédictive pour une utilité clinique dans la prise en charge du cancer du sein

Epirubicin-Based Chemotherapy in Metastatic Breast Cancer Patients: Role of Dose-Intensity and Duration of Treatment

Oncogénétique: estimation des besoins de la population en France pour les dix ans à venir

Cancer genetics: estimation of the needs of the population in France for the next ten years

335PBreast cancer (BC) treatment (tx) with everolimus (EVE) and exemestane (EXE) in hormone receptor positive (HR+)/ HER2-negative (HER2−) postmenopausal women: Final analysis of the French observational TANGO study

Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1 2 mutations

Prise en charge des cancers du sein : le changement, c’est maintenant

Role of interstitial brachytherapy in oral and oropharyngeal carcinoma: Reflection of a series of 1344 patients treated at the time of initial presentation

1568P - The Use of Biosimilar Epoetins in the Management of Chemotherapy-Induced Anaemia (CIA) in Patients with Breast Cancer: A Subanalysis of the Orheo Study

The Use of Biosimilar Epoetins in the Management of Chemotherapy-Induced Anaemia (CIA) in Patients with Breast Cancer: A Subanalysis of the Orheo Study

The Use of Biosimilars in the Management of Chemotherapy-Induced Anaemia (CIA) in Solid Tumours, Lymphoma and Myeloma: the Orheo Study

The Use of Biosimilar Epoetins in the Management of Chemotherapy-Induced Anaemia (CIA) in Patients with Lung Cancer: A Subanalysis of the Orheo Study

1563P - The Use of Biosimilars in the Management of Chemotherapy-Induced Anaemia (CIA) in Solid Tumours, Lymphoma and Myeloma: the Orheo Study

1569P - The Use of Biosimilar Epoetins in the Management of Chemotherapy-Induced Anaemia (CIA) in Patients with Lung Cancer: A Subanalysis of the Orheo Study

Breast cancer clinical practice recommendations from Saint-Paul-de-Vence: excerpts concerning targeted therapies: Cours supérieur francophone de cancérologie, Saint-Paul-de-Vence

Abstract P2-12-02: Characteristics of the BRCA mutation profile of a population of patients with triple negative breast cancer

Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas

Summary version of the standards, options and recommendations for nonmetastatic breast cancer (updated January 2001)

Place des biosimilaires de l’époétine dans le traitement des anémies secondaires à une chimiothérapie pour cancer des poumons : sous-analyse de l’étude ORHEO

Suchergebnisse filtern